| Autor: |
Lancet, J E, Rapoport, A P, Brasacchio, R, Eberly, S, Raubertas, R F, Linder, T, Muhs, A, Duerst, R E, Abboud, C N, Packman, C H, DiPersio, J F, Constine, L S, Rowe, J M, Liesveld, J L |
| Předmět: |
|
| Zdroj: |
Bone Marrow Transplantation; 8/1/98, Vol. 22 Issue 3, p265, 7p |
| Abstrakt: |
Seventy consecutive patients with refractory or relapsed Hodgkin’s disease who received high-dose chemotherapy followed by autologous stem cell rescue were analyzed to identify clinically relevant predictors of long-term event-free survival. High-dose therapy consisted primarily of carmustine (BCNU), etoposide, cytarabine and cyclophosphamide (BEAC). The 5-year Kaplan–Meier event-free survival (EFS) for the entire cohort was 32% (95% confidence interval; 18–45%) with a median follow-up of 3.6 years (range 7 months–7.6 years). The most significant predictor of improved survival was the presence of minimal disease (defined as all areas 2 cm) at the time of transplant: the 5 years EFS was 46 vs 10% for patients with bulky disease (P = 0.0002). Other independent predictors identified by step-wise regression analysis included the presence of non-refractory disease and the administration of post-transplant involved-field radiotherapy (XRT). Treatment-related mortality occurred in 13 of 70 patients: nine patients (13%) died within the first 100 days, mainly from cardiopulmonary toxicity. However, only one of 24 patients (4%) transplanted during the last 4.5 years died from early treatment-related complications. While high-dose therapy followed by autotransplantation led to long-term EFS of 50% for patients with favorable prognostic factors, a substantial proportion of patients relapsed, indicating that new therapeutic strategies are needed. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
